Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma

Cancer Biology and Therapy

Volumn 10, Issue 11, 2010, Pages 1091-1097

  Fateh, Salman ^a   Schell, Todd D ^a   Gingrich, Rebecca ^a   Neves, Rogerio I ^a   Drabick, Joseph J ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

High dose IL 2; Melanoma; Metastatic; T reg lymphocytes; Temozolomide

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MELANOMA; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY; REGULATORY T LYMPHOCYTE; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 78649863803     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.11.13452     Document Type: Article

References (14)

1. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: An overview. Oncology 2009; 23:488-96.
2. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000; 18:158-66.
3. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: A systemic review. Oncologist 2007; 12:1114-23.
4. Atkins MB, Kunzel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: Long term survival update. Cancer J Sci Am 2000; 6:11-4.
5. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14:5610-8.
6. Tarhini AA, Kirkwood JM, Gooding WE, Moschos S, Agarwala SS. A Phase 2 Trial of Sequential Temozolomide Chemotherapy Followed by High-Dose Interleukin-2 Immunotherapy for Metastatic Melanoma. Cancer 2008; 11397:1632-40.
7. + lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22:610-6.
8. + regulatory T cells in patients treated with high dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169-77.
9. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009; 58:1627-34.
10. Neyns B, Tosoni A, Hwu WJ, Reardon DA. Dose-dense temozolomide regimens. Cancer 2010; 116:2868-77.
11. + regulatory T cells in the human immune system. Nat Rev Immunol 2010; 10:490-500.
12. Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol 2008; 127:123-9. (Pubitemid 351474602)
13. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043-53.
14. High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma: NCT 01124734: http://clinicaltrials.gov/ct2/show/ NCT01124734.